Interferon-α Salvage Treatment is Effective for Patients with Acute Leukemia/myelodysplastic Syndrome with Unsatisfactory Response to Minimal Residual Disease-Directed Donor Lymphocyte Infusion after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaodong Mo,Xiaohui Zhang,Lanping Xu,Yu Wang,Chenhua Yan,Huan Chen,Yuhong Chen,Wei Han,Fengrong Wang,Jingzhi Wang,Kaiyan Liu,Xiaojun Huang

DOI: https://doi.org/10.1007/s11684-017-0599-3

2015-01-01

Biology of Blood and Marrow Transplantation

Abstract:The efficacy of salvage interferon-α (IFN-α) treatment was investigated in patients with unsatisfactory response to minimal residual disease (MRD)-directed donor lymphocyte infusion (DLI) (n=24). Patients who did not become MRD-negative at 1 month after DLI were those with unsatisfactory response and were eligible to receive salvage IFN-α treatment within 3 months of DLI. Recombinant human IFN-α-2b injections were subcutaneously administered 2–3 times a week for 6 months. Nine (37.5%), 6 (25.0%), and 3 (12.5%) patients became MRD-negative at 1, 2, and>2 months after the salvage IFN-α treatment, respectively. Two-year cumulative incidences of relapse and non-relapse mortality were 35.9% and 8.3%, respectively. Two-year probabilities of event-free survival, disease-free survival, and overall survival were 51.6%, 54.3%, and 68.0%, respectively. Outcomes of patients subjected to salvage IFN-α treatment after DLI were significantly better than those with persistent MRD without IFN-α treatment. Moreover, clinical outcomes were comparable between the salvage DLI and IFN-α treatment groups. Thus, salvage IFN-α treatment may help improve the outcome of patients with unsatisfactory responses to MRD-directed DLI and could be a potential salvage treatment for these patients after allogeneic hematopoietic stem cell transplantation.